Treatment of drug-resistant neuroblastoma cells with doxorubicin and pan-caspase inhibitor (Q-VD-OPH) significantly decreased cell viability and senescence phenotype, as evidenced by an increased p21/WAF1 expression, senescence-associated β-galactosidase activity, and cell growth arrest. This evidence concerns the gene CDKN1A and neuroblastoma.